Tang Kuo-Tung, Hsieh Tsu-Yi, Chao Ya-Hsuan, Lin Meng-Xian, Chen Yi-Hsing, Chen Der-Yuan, Lin Chi-Chen
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, R.O.C.
Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, R.O.C.
PLoS One. 2017 May 30;12(5):e0178404. doi: 10.1371/journal.pone.0178404. eCollection 2017.
Many studies have demonstrated elevated circulating levels of high-mobility group box 1 (HMGB1) and decreased circulating levels of soluble receptor for advanced glycation end products (sRAGE) in patients with autoimmune diseases. In the present study, we investigated plasma levels of both HMGB1 and sRAGE in primary antiphospholipid syndrome (pAPS) patients.
We prospectively recruited 11 pAPS patients, 17 antiphospholipid antibody (APA)-positive SLE patients without APS manifestations (APA+SLE) and 12 SLE patients with secondary APS (APS+SLE). We also recruited 10 healthy controls (HCs). Plasma levels of HMGB1 and sRAGE were determined using sandwich ELISA kits. In addition, plasma levels of HMGB1 were also determined using Western blot in 6 pAPS patients and 6 HCs.
There was no significant difference in plasma levels of HMGB1 measured by ELISA among subgroups of the enrolled subjects. In addition, there was no significant difference in plasma levels of HMGB1 measured by Western blot between pAPS patients and HCs. On the other hand, we observed a trend toward lower plasma levels of sRAGE in APA+SLE or APS+SLE patients when compared with HCs. However, there was no significant difference in plasma levels of sRAGE between pAPS patients and HCs, or between APA+SLE patients and APS+SLE patients.
There was no significant difference in plasma levels of sRAGE or HMGB1 between pAPS patients and HCs. Plasma levels of sRAGE/HMGB1 could not be utilized to differentiate between APA+SLE and APS+SLE patients.
许多研究表明，自身免疫性疾病患者循环中高迁移率族蛋白B1（HMGB1）水平升高，而晚期糖基化终产物可溶性受体（sRAGE）循环水平降低。在本研究中，我们调查了原发性抗磷脂综合征（pAPS）患者血浆中HMGB1和sRAGE的水平。
我们前瞻性招募了11例pAPS患者、17例无APS表现的抗磷脂抗体（APA）阳性SLE患者（APA+SLE）和12例继发性APS的SLE患者（APS+SLE）。我们还招募了10名健康对照者（HCs）。使用夹心ELISA试剂盒测定血浆中HMGB1和sRAGE的水平。此外，还对6例pAPS患者和6例HCs使用蛋白质印迹法测定了血浆中HMGB1的水平。
在纳入的受试者亚组中，通过ELISA测定的血浆HMGB1水平无显著差异。此外，pAPS患者和HCs之间通过蛋白质印迹法测定的血浆HMGB1水平也无显著差异。另一方面，我们观察到，与HCs相比，APA+SLE或APS+SLE患者血浆中sRAGE水平有降低的趋势。然而，pAPS患者与HCs之间，或APA+SLE患者与APS+SLE患者之间，血浆中sRAGE水平无显著差异。
pAPS患者与HCs之间血浆中sRAGE或HMGB1水平无显著差异。血浆中sRAGE/HMGB1水平不能用于区分APA+SLE和APS+SLE患者。
